MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten
Phase 2 Study of Mavacamten Targeting Subgroup of Patients with Diastolic Heart Failure (HFpEF) Anticipated to Begin in the Second Quarter of 2020 Conference Call Today at 8:30 a.m. ET (5:30 a.m. PT) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results